Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Wednesday, May 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences is set to present late-breaking data at the EASL Congress 2024. The presentation will focus on the latest preclinical safety data for PBGENE-HBV, which is crucial for upcoming regulatory filings. This highlights the company's commitment to advancing its gene editing platform.
Price reaction · baseline $10.41 (2024-04-30 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of new preclinical safety data.
  • Preparation for regulatory filings in 2024.
  • Showcases advancements in gene editing technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 DURHAM, N.C. –(BUSINESS WIRE)–May 1, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform

Frequently Asked Questions

What data will Precision BioSciences present at EASL 2024?

They will present preclinical safety data for PBGENE-HBV.

Why is the presentation important?

It is crucial for their upcoming regulatory filings in 2024.

What platform does Precision BioSciences use?

They utilize their proprietary ARCUS® gene editing platform.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences EASL Congress 2024 PBGENE-HBV gene editing regulatory filings
Last updated: May 1, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →